Twist Bioscience Corporation (TWST) Stock

Twist Bioscience Corporation (TWST) is a Healthcare stock trading at $136.31 (as of 2026-08-20), with a market capitalization of $8.49B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products, including synthetic genes and tools such as sample preparation reagents and antibody libraries used in drug discovery and development. It also offers DNA-based digital data storage solutions and works with partners on sequencing and antibody collaboration efforts.

Understand Twist Bioscience Corporation: how it makes money

Twist Bioscience makes and sells synthetic DNA-based products using its platform that writes DNA on a silicon chip, including synthetic genes, sample preparation tools, antibody libraries for drug discovery and development, and DNA-based digital data storage.

The profit model depends on scaling revenue from NGS applications and DNA synthesis and protein solutions to cover large operating expenses, since the latest reported period shows an operating margin of -41.4% with operating expenses (excluding cost of revenues and litigation settlement costs) roughly matching revenue.

Revenue by segment (latest quarter)
NGS Apps	$0.1B
DSPS	$0.1B

Business quality (Weak): Clear business description and segment-like revenue buckets are provided, but gross margin is missing, and the operating KPI set centers on revenue and operating expense levels rather than product volume or customer metrics.

Bull case

Broad synthetic DNA product set: The company sells multiple synthetic DNA-based offerings, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as digital data storage.
Revenue tied to two main platform applications: Reported revenue can be viewed through NGS applications and DNA synthesis and protein solutions (DSPS), linking demand to use cases built on the same DNA synthesis platform.
Collaboration-driven commercialization: The company has collaboration agreements with Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc, deepCDR Biologics AG, and Centogene N.V.

Bear case

Material operating losses: The latest quarter shows operating margin of -41.4%, indicating the company did not cover operating costs from revenue.
Operating expense intensity: Operating expenses (excluding cost of revenues and litigation settlement costs) are about the same order of magnitude as revenue in the latest reported period, leaving less cushion if revenue growth slows.
Limited visibility into profitability drivers: Gross margin is not provided in the available facts, which makes it harder to separate pricing and mix effects from cost structure when assessing progress.

Valuation — source: SEC EDGAR (first-party)
Price	$136.31
Market Cap	$8.49B
Price / Book	19.04
Price / Sales	19.66
FCF Yield	-1.1%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$376.57M
Net Margin	-20.6%
Return on Equity	-30.7%
Current Ratio	2.67
Revenue Growth (YoY)	23.2%
EPS Growth (YoY)	-264.7%
FCF Growth (YoY)	-18.1%

Financial Health — source: SEC EDGAR
Altman Z-Score	27.07 (safe)

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.6
Industry P/E (Pharmaceutical Products)	17.2

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Artisan Partners Limited Partnership ($302.60M)
Institutional Holders Tracked	10
Congressional Trades (recent)	2

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Emily Marine Leproust
Employees	923
Country	US
IPO Date	2018-10-31

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.